NewAmsterdam Pharma Co NV (NAMS) Reiterated at Buy by Stifel

September 8, 2026 6:55 AM

Stifel analyst James Condulis reiterated a Buy rating and $50.00 price target on NewAmsterdam Pharma Co NV (NASDAQ: NAMS).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found